BRIEF published on 08/12/2024 at 13:05, 1 year 5 months ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 1 year 5 months ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 1 year 6 months ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 6 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 7 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 7 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 7 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 7 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 01/31/2026 at 03:15, 1 day 15 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 17 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 20 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 1 day 3 hours ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 6 hours ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 16 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 21 hours ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 22 hours ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 17:45, 2 days 1 hour ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 3 days 1 hour ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 3 days 1 hour ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 3 days 1 hour ago Cegedim generated LFL revenue growth of 1.1% in 2025
